Mission Statement, Vision, & Core Values (2024) of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

A Brief History of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, established in 1998, is a key player in the pharmaceutical industry in China, focusing on the development, production, and marketing of various medications, particularly in the fields of oncology and cardiology.

Over the years, the company has significantly expanded its operations and product offerings. As of 2023, the company boasts a portfolio of over 300 registered medications across multiple therapeutic areas, enhancing its competitive position in the rapidly growing Chinese pharmaceutical market.

In 2021, Sunshine Guojian reported a total revenue of approximately ¥1.2 billion (around $185 million), showcasing a growth rate of 15% year-over-year. The net profit for the same year was approximately ¥150 million (about $23 million), indicating a strong financial performance.

The company's growth trajectory is also reflected in its R&D investments. In 2022, Sunshine Guojian allocated ¥180 million (about $27.7 million) to R&D, which represented 15% of its total revenues. This focus on innovation has led to the successful launch of dozens of new products.

The company's strategic partnerships have also played a pivotal role in its success. In 2020, Sunshine Guojian entered a joint venture with a leading European pharmaceutical firm, which enabled the company to enhance its distribution channels and gain access to advanced technology. This partnership has streamlined its production processes, resulting in improved efficiency and reduced costs.

Sunshine Guojian's commitment to quality is evident in its compliance with international standards. The company's facilities are certified by various global regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This has allowed the company to export its products to several international markets, further driving its growth.

As of 2023, the company's stock is listed on the Shanghai Stock Exchange under the ticker symbol 600500. The stock has shown resilience, with a market capitalization of approximately ¥8 billion (about $1.25 billion), reflecting investor confidence in its long-term prospects. The price-to-earnings (P/E) ratio stands at 35, which is competitive within the pharmaceutical sector.

In recent years, the company has placed a strong emphasis on corporate social responsibility, particularly in the areas of public health and environmental sustainability. Sunshine Guojian actively participates in community health initiatives, demonstrating its commitment to improving healthcare access across China.

Looking forward, Sunshine Guojian plans to expand its research efforts, focusing on innovative therapies and personalized medicine to meet the evolving needs of patients and healthcare providers. With a robust pipeline of new products and a strategic vision for growth, the company is well-positioned to capitalize on opportunities in the pharmaceutical sector.

A Who Owns Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd operates within the pharmaceutical sector in China. As of the latest data available, the company's ownership structure primarily consists of private investors and institutional stakeholders.

The largest shareholder is Sunshine Guojian Investment Co., Ltd, which holds a significant stake of approximately 45% of the company. Other notable shareholders include various investment firms and individuals.

• Sunshine Guojian Investment Co., Ltd: 45%
• China Life Insurance Company: 10%
• Guangdong Securities: 5%
• Individual investors: 40%

According to the 2022 Annual Report, Sunshine Guojian Pharmaceutical recorded total assets of ¥1.2 billion and liabilities amounting to ¥600 million. Their revenue for the fiscal year was approximately ¥800 million, reflecting a growth rate of 15% year-over-year.

The company's net profit margin stood at 10%, indicating effective cost management and operational efficiency. The total equity held by shareholders was approximately ¥600 million.

The company is listed on the Shanghai Stock Exchange, and its stock performance has shown resilience with a market capitalization of around ¥1 billion as of October 2023. The stock price has seen fluctuations but maintained an average increase of 8% over the past year.

In terms of governance, the board of directors includes industry veterans with extensive experience in pharmaceutical management, finance, and corporate strategy. The management team emphasizes research and development, which is reflected in their allocation of 12% of annual revenue toward innovative projects.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Mission Statement

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd is dedicated to advancing health and wellness through innovative pharmaceuticals. Their mission statement emphasizes a commitment to quality, accessibility, and technological advancement in the pharmaceutical industry. They strive to enhance the quality of life through the development of effective and safe medications.

The company's focus includes developing high-quality generic and specialty pharmaceuticals, ensuring they adhere to stringent international standards. With a commitment to research and development, Sunshine Guojian invests significantly in innovative solutions that address unmet health needs.

Sunshine Guojian aims to achieve sustainability in the pharmaceutical sector, targeting a reduction in carbon footprint by 30% by the year 2025. This aligns with their commitment to not just health but also environmental responsibility.

The company also emphasizes accessibility, striving to enhance the distribution network to reach underserved areas. Currently, they distribute products to over 30 countries, with plans to expand into 10 new markets by 2024.

Furthermore, Sunshine Guojian is compliant with the latest Good Manufacturing Practices (GMP), ensuring their products meet the highest quality standards. They have invested over ¥200 million in upgrading facilities to comply with international regulations.

Lastly, customer trust and satisfaction are paramount. Recent surveys indicate a customer satisfaction rate of over 85%, reflecting their commitment to quality and service. The company's focus on innovation is also underlined by the introduction of 15 new products in the last year, contributing to a revenue growth of 20% year-over-year.

How Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Works

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, established in 1996, specializes in the development, production, and sale of pharmaceuticals, particularly focusing on innovative drug formulations. The company operates under stringent quality standards, ensuring compliance with international pharmaceutical regulations.

As of October 2023, Sunshine Guojian's revenue is reported at approximately RMB 2.1 billion (around $290 million), reflecting a year-on-year growth of 15%. The company's net profit margin stands at 12%, indicative of effective cost management and operational efficiency.

The company’s primary product categories include:

• Generic Drugs
• Active Pharmaceutical Ingredients (APIs)
• Diagnostic Kits
• Healthcare Products

Sunshine Guojian operates three major production facilities in Shanghai, Xuzhou, and Chengdu, each adhering to Good Manufacturing Practices (GMP). These facilities have a combined production capacity of over 10 million units annually. The company invests around RMB 150 million (about $21 million) yearly on research and development, aiming to introduce at least 5 new products to the market each year.

The company's strategic partnerships with hospitals and healthcare institutions enhance its market penetration. Sunshine Guojian’s export business accounts for 30% of its total sales, with key markets including Southeast Asia, Africa, and South America.

Sunshine Guojian focuses heavily on product innovation. For instance, its flagship product, a pain management solution, saw sales of RMB 300 million (approximately $42 million) in the last fiscal year. This product contributed significantly to the company's overall success. The company also holds several patents related to drug delivery systems.

Financially, the company's total assets are valued at approximately RMB 3 billion (around $420 million), with liabilities at RMB 1 billion (about $140 million), resulting in a debt-to-equity ratio of 0.5.

In recent years, Sunshine Guojian has expanded its digital health initiatives, investing over RMB 100 million (approximately $14 million) in telemedicine and health monitoring technologies, targeting the growing demand for digital healthcare solutions.

As of the latest report, Sunshine Guojian's stock trades on the Shanghai Stock Exchange under the ticker number 603392. The stock has shown a price appreciation of 25% year-to-date, driven by positive earnings reports and expanding product lines.

How Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Makes Money

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd operates primarily in the pharmaceutical industry, focusing on the research, development, manufacturing, and sale of various pharmaceutical products. The company generates revenue through multiple streams, including drug sales, licensing agreements, and partnerships with healthcare providers.

In the fiscal year 2022, Sunshine Guojian reported total revenue of approximately RMB 1.5 billion, marking an increase of 15% from the previous year. Drug sales represent the largest portion of this revenue, accounting for around 80%, or approximately RMB 1.2 billion.

The company's product portfolio includes generic drugs, proprietary medicines, and over-the-counter (OTC) products. Some of the key therapeutic areas focus on cardiovascular diseases, oncology, and infectious diseases. The following table provides a breakdown of revenue by product category:

In addition to direct drug sales, the company has entered into licensing agreements with global pharmaceutical firms, which provide substantial revenue. Licensing fees and royalties contributed approximately RMB 300 million in fiscal year 2022, representing a 20% increase year-over-year.

Strategically, Sunshine Guojian focuses on expanding its research and development (R&D) capabilities. In 2022, the company allocated RMB 200 million to R&D, which constitutes about 13% of its total revenue. This investment aims to strengthen the pipeline for new drug development, particularly in biologics and innovative therapies.

The company also benefits from partnerships with various healthcare providers and institutions, which allow for collaborative research and distribution of products. These partnerships have been instrumental in enhancing market reach and increasing revenue from specialty medications.

Sunshine Guojian continues to explore new market opportunities, particularly in international markets, which presents a pathway for increasing revenue. The export of its products accounted for about 25% of total sales in 2022, amounting to RMB 375 million.

Another revenue driver is the growing demand for healthcare products as China expands its healthcare infrastructure. The implementation of policies to improve access to healthcare is expected to create more opportunities for growth in pharmaceutical sales, aligning with Sunshine Guojian’s strategic objectives.

The company's gross profit margin stood at 45% in 2022, reflecting efficient production processes and favorable pricing strategies. Net income for the year was reported at approximately RMB 300 million, yielding a net profit margin of 20%.